| Timolol vs placebo | No demonstrated result suggested reinfarction by 38% (not demonstrated) suggested Sudden death by 51% (not demonstrated) suggested Cardiovascular death by 42% (not demonstrated) suggested cardiac death by 42% (not demonstrated) suggested All cause death by 36% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| reinfarction | 0.62 [0.47 0.82] | p=0.04 | 0 | 1884 | 1 | Norwegian Multicentre Study Group , | | cardiac event (fatal and non fatal ) | no data | | Sudden death | 0.49 [0.34 0.71] | p=0.04 | 0 | 1884 | 1 | Norwegian Multicentre Study Group , | | cardiovascular events | no data | | Cardiovascular death | 0.58 [0.44 0.77] | p=0.04 | 0 | 1884 | 1 | Norwegian Multicentre Study Group , | | myocardial infarction (fatal and non fatal) | no data | | cardiac death | 0.58 [0.44 0.77] | p=0.04 | 0 | 1884 | 1 | Norwegian Multicentre Study Group , | | All cause death | 0.64 [0.49 0.84] | p=0.04 | 0 | 1884 | 1 | Norwegian Multicentre Study Group , |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
